---
layout: post
title: "Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; International Council for Harmonisation; Guidance for Industry; Availability"
date: 2026-02-05 19:09:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-09963
original_published: 2021-05-12 00:00:00 +0000
significance: 8.00
---

# Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; International Council for Harmonisation; Guidance for Industry; Availability

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** May 12, 2021 00:00 UTC
**Document Number:** 2021-09963

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management." The guidance was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation. The guidance, which consists of a Guidance and Annexes, provides a framework to facilitate the management of postapproval chemistry, manufacturing, and controls changes for new and marketed pharmaceutical drug substances and drug products, including chemical and biotechnological/biological products. This guidance finalizes the draft guidance of the same title issued on May 31, 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/05/12/2021-09963/q12-technical-and-regulatory-considerations-for-pharmaceutical-product-lifecycle-management)
- API: https://www.federalregister.gov/api/v1/documents/2021-09963

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
